p38 MAP kinase inhibitors as anti inflammatory agents

Mini-Reviews in Medicinal Chemistry

Volumn 13, Issue 14, 2013, Pages 2082-2096

  Amir, Mohammad ^a   Somakala, K ^a   Ali, Sazid ^a  

^a HAMDARD UNIVERSITY   (India)

Author keywords

Anti inflammatory; Imidazole; Kinases; p38 inhibitors; Pyrazolyl urea; Urea

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL) IMIDAZOLE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 (4 FLUOROPHENYL) 2 (5 METHYL 5 MORPHOLINOCARBONYL 1,3 DIOXAN 2 YL) 5 (4 PYRIDINYL)IMIDAZOLE; 5 (4 PYRIDINYL) 4 (4 FLUOROPHENYL) 1 (3 MORPHOLINOPROPYL)IMIDAZOLE; AMIDE; ANTIINFLAMMATORY AGENT; CP 808844; CYCLOOXYGENASE 2; CYTOKINE; GK 00687; HETEROCYCLIC COMPOUND; IMIDAZOLE DERIVATIVE; INDOLE DERIVATIVE; INTERLEUKIN 1BETA; LASS BIO 998; MATRIX METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; PYRAZOLE DERIVATIVE; PYRAZOLOHETEROARYL DERIVATIVE; PYRIDAZINE DERIVATIVE; PYRIDINE DERIVATIVE; RO 3201195; RPR 200765 A; SC 102; TALMAPIMOD; TRIAZOLOPYRIDINE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UREA;

ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; ARTICLE; CELL ASSAY; CHRONIC ARTHRITIS; CRYSTALLOGRAPHY; DISEASE COURSE; DRUG EFFICACY; DRUG POTENCY; HUMAN; IC 50; INFLAMMATION; NONHUMAN; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION;

AMIDES; ANIMALS; ANTI-INFLAMMATORY AGENTS; ARTHRITIS; BINDING SITES; CYCLOOXYGENASE 2; CYTOKINES; DISEASE MODELS, ANIMAL; HUMANS; IMIDAZOLES; INDOLES; INFLAMMATION; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIDINES; STRUCTURE-ACTIVITY RELATIONSHIP; UREA;

EID: 84893010726     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/13895575113136660098     Document Type: Article

References (78)

1. Davies, S. P.; Reddy, H.; Caivano, M.; Cohen, P. Specificity and mechanism of action of some commonly used protein kinases inhibitors. Biochem. J., 2000, 351, 95-105.
2. Sherwood, E. R.; Toliver-Kinsky, T. Mechanisms of the inflammatory response. Best Pract. Res. Clin. Anaesthesiol., 2004, 18, 385-405.
3. Lee, J. C.; Laydon, J. T.; McDonnell, P. C.; Gallagher, T. F.; Kumar, S.; Green, D.; McNulty, D.; Blumenthal, M. J.; Heys, J. R.; Landvatter, S. W.; Strickler, J. E.; McLaughlin, M. M.; Siemens, I. R.; Fisher, S. M.; Livi, G. P.; White, J. R.; Adams, J. L.; Young, P. R. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature, 1994, 372, 739-746.
4. Badger, A. M.; Bradbeer, J. N.; Votta, B.; Lee, J. C.; Adams, J. L.; Griswold, D. E. Pharmacological profile of SB 20 a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function. J. Pharmacol. Exp. Ther., 1996, 279, 1453-1461.
5. Lee, M. R.; Dominguez, C. MAP kinase p38 inhibitors: clinical results and an intimate look at their interactions with p38alpha protein. Curr. Med. Chem., 2005, 12, 2979-2994.
6. Feldmann, M.; Brennan, F. M.; Maini, R. N. Rheumatoid arthritis. Cell, 1996, 85, 307-310.
7. Lee, J. C.; Kassis, S.; Kumar, S.; Badger, A.; Adams, J. L. p38 Mitogen activated protein kinase inhibitors-mechanisms and therapeutic potentials. Pharmacol. Ther. 1999, 82, 389-397.
8. Schindler, J. F.; Monahan, J. B.; Smith, W. G. p38 Pathway kinases as anti-inflammatory drug targets. J. Dent. Res., 2007, 86(9), 800-811.
9. Traxler, P. & Furet, P. Strategies toward the design of novel and selective protein tyrosine kinase inhibitors. Pharmacol. Ther., 1999, 82, 195-206.
10. Mol, C. D.; Fabbro, D.; Hosfield, D. J. Structural insights into the conformational selectivity of STI-571 and related kinase inhibitors. Curr. Opin. Drug Discov. Devel., 2004, 7, 639-648.
11. Gum, R. J.; McLaughlin, M. M.; Kumar, S.; Wang, Z.; Bower, M. J.; Lee, J. C.; Adams, J. L.; Livi, G. P.; Goldsmith, E. J.; Young, P. R. Acquisition of sensitivity of stress-activated protein kinases to the p38 inhibitor, SB 203580, by alteration of one or more amino acids within the ATP binding pocket. J. Biol. Chem., 1998, 273, 15605-15610.
12. Lisnock, J.; Tebben, A.; Frantz, B.; O'Neill, E. A.; Croft, G.; O'Keefe, S. J.; Li, B.; Hacker, C.; de Laszlo, S.; Smith, A.; Libby, B.; Liverton, N.; Hermes, J.; LoGrasso, P. Molecular basis for p38 protein kinase inhibitor specificity. Biochemistry, 1998, 37, 16573-16581.
13. Laufer, S. A.; Hans-Gunther S.; Wagner, G. K. Imidazole inhibitors of cytokine release: Probing substituents in the 2 position. J. Med. Chem., 2002, 45, 4695-4705.
14. Toledo, L. M.; Lydon, M. B.; Elbaum, D. The structure-based design of ATP-site directed protein kinase inhibitors. Curr. Med. Chem., 1999, 6, 775-805.
15. Tong, L.; Pav, S.; White, D. M.; Rogers, S.; Crane, K. M.; Cywin, C. L.; Brown, M. L.; Pargellis, C. A. A highly specific inhibitor of human p38 MAP kinase binds in the ATP pocket. Nat. Struct. Biol., 1997, 4, 311-316.
16. Wilson, K. P.; McCaffrey, P. G.; Hsio, K.; Pazhanisamy, S.; Alullo, V.; Bems, G. W. The structural basis for the specificity of pyridinylimidazole inhibitors of p38 MAP kinase. Chem. Biol., 1997, 4, 423-431.
17. Wang, Z.; Canagarajah, B. J.; Boehm, J. C.; Kassisa, S.; Cobb, M. H.; Ycung, P. R. Structural basis of inhibitor selectivity in MAP kinases. Structure, 1998, 6, 1117-1128.
18. Gallagher, T. F.; Siebel, G. L.; Kassis, S.; Laydon, J. T.; Blumenthal, M. J.; Lee, J. C.; Lee, D.; Boehm, J. C.; Fier-Thompson, S. M.; Abt, J. W.; Sorenson, M. E.; Smietana, J. M.; Hall, R. F.; Garigipati, R. S.; Bender, P. E.; Erhard, K. F.; Krog, A. J.; Hofamnn, G. A.; Sheldrake, P. L.; McDonnell, P. C.; Kumar, S.; Young, P. R.; Adams, J. L. Regulation of stress-induced cytokine production by pyridinylimidazoles; Inhibition of CSBP kinase. Bioorg. Med. Chem., 1997, 5, 49-64.
19. Boehm, J. C.; Smietana, J. M.; Sorenson, M. E.; Garigipati, R. S.; Gallagher, T. F.; Sheldrake, P. L.; Bradbeer, J.; Badger, A. M.; Laydon, J. T.; Lee, J. C.; Hillegass, L. M.; Griswold, D. E.; Breton, J. J.; Chabot-Fletcher, M. C.; Adams, J. C. 1-Substituted 4-aryl-5-pyridinylimidazoles: A new class of cytokine suppressive drugs with low 5-lipoxygenase and cyclooxygenase inhibitory potency. J. Med. Chem., 1996, 39, 3929-3937.
20. Jerry L. Adams, Jeffrey C. Boehm, Shouki Kassis, Peter D. Gorycki, Edward F. Webb, Ralph Hall, Margaret Sorenson, John C. Lee, Andrew Ayrton, Don E. Griswold, Timothy F. Gallagher. Pyridinylimidazole inhibitors of CSBP/p38 kinase demonstrating decreased inhibition of hepatic cytochrome P450 enzymes. Bioorg. Med. Chem. Lett., 1998, 8, 3111-3116.
21. Nigel J. Liverton, John W. Butcher, Christopher F. Claiborne, David A. Claremon, Brian E. Libby, Kevin T. Nguyen, Steven M. Pitzenberger, Harold G. Selnick, Garry R. Smith, Andrew Tebben, Joseph P. Vacca, Sandor L. Varga, Lily Agarwal, Kim Dancheck, Amy J. Forsyth, Daniel S. Fletcher, Betsy Frantz, William A. Hanlon, Coral F. Harper, Scott J. Hofsess, Matthew Kostura, Jiunn Lin, Sylvie Luell, Edward A. O'Neill, Chad J. Orevillo, Margaret Pang, Janey Parsons, Anna Rolando, Yousif Sahly, Denise M. Visco, and Stephen J. O'Keefe. Design and Synthesis of potent, selective, and orally bioavailable tetrasubstituted imidazole inhibitors of p38 Mitogen-Activated Protein Kinase. J. Med. Chem., 1999, 42, 2180-2190.
22. Iain M. Mclay, Frank Halley, John E. Souness, Jeffrey McKenna, Veronique Benning, Mark Birrell, Brenda Burton, Maria Belvisi, Alan Collis, Alex Constan, Martyn Foster, David Hele, Zaid Jayyosi, Mike Kelley, Chris Maslen, Glen Miller, Marie-Claude Ouldelhkim, Kenneth Page, Simon Phipps, Kenneth Pollock, Barry Porter, Andrew J. Ratcliff, Elisabeth J. Redford, Stefen Webber, Bryan Slater, Veronique Thybaud, Nicole Wilsher. The discovery of RPR200765A, a p38 MAP Kinase inhibitor displaying a good oral anti-arthritic activity. Bioorg. Med. Chem. Lett., 2001, 9, 537-554.
23. Boehm, J. C.; Bower, M. J.; Gallagher, T. F.; Kassis, S.; Johnson, S. R.; Adams, J. L. Phenoxypyrimidine Inhibitors of p38 Kinase: Synthesis and statistical evaluation of the p38 inhibitory potencies of a series of 1-(piperidin-4-yl)-4-(4-fluorophenyl)-5-(2-phenoxypyrimidin-4-yl) imidazoles. Bioorg. Med. Chem. Lett., 2001, 11, 1123-1126.
24. Adams, J. L.; Boehm, J. C.; Gallagher, T. F.; Kassis, S.; Webb, E.; Hall, R.; Sorenson, M.; Garigipati, R. S.; Griswold, D. E.; Lee, J. C Pyrimidinylimidazole inhibitors of p38: Cyclic N-1 imidazole substituents enhance p38 Kinase inhibition and oral activity. Bioorg. Med. Chem. Lett., 2001, 11, 2867-2870.
25. Laufer, S. A.; Wagner, G. K.; Kotschenreuther, D. A.; Albrecht, D. Novel substituted pyridinyl imidazoles as potent anticytokine agents with low activity against hepatic cytochrome P450 enzymes. J. Med. Chem., 2003, 46, 3230-3244.
26. Laufer, S. A.; Zimmermann, W.; Ruff, K. J. Tetrasubstituted imidazole inhibitors of cytokine release: probing substituents in the N-1 position. J. Med. Chem., 2004, 47, 6311-6325.
27. Laufer, S. A.; Hauser, D. R. J.; Domeyer, D. M.; Kinkel, D.; Liedtke, A. J. Design, Synthesis and biological evaluation of novel tri-and tetrasubstituted imidazoles as highly potent and specific ATPMimetic inhibitors of p38 MAP Kinase: Focus on optimized interactions with the enzyme's surface-exposed front region. J. Med. Chem., 2008, 51, 4122-4149.
28. Laufer, S.; Hauser, D.; Stegmiller, T.; Bracht, C.; Ruff, K.; Schattel, V.; Albrecht, W.; Koch, P. Tri-and tetrasubstituted imidazoles as p38 Mitogen-Activated Protein Kinase inhibitors. Bioorg. Med. Chem. Lett., 2010, 20, 6671-6675.
29. Rupert, K. C.; Henry, J. R.; Dodd, J. H.; Wadsworth, S. A.; Cavender, D. E.; Olini, G. C.; Fahmy, G.; Siekierka, J. J. Imidazopyrimidines, Potent Inhibitors of p38 MAP Kinase. Bioorg. Med. Chem. Lett., 2003, 13, 347-350.
30. Dombroski, M. A.; Letavic, M. A.; McClure, K. F.; Barberia, J. T.; Carty, T. J.; Cortina, S. R.; Csiki, C.; Dipesa, A. J.; Elliott, N. C.; Gabel, C. A.; Jordan, C. K.; Labasi, J. M.; Martin, W. H.; Peese, K. M.; Stock, I. A.; Svensson, L.; Sweeney, F. J.; Chul H. Yu. Benzimidazolone p38 inhibitors. Bioorg. Med. Chem. Lett., 2004, 14, 919-923.
31. Revesz, L.; Blum, E.; Di Padova, F. E.; Buhl, T.; Feifel, R.; Gram, H.; Hiestand, P.; Manning, U.; Rucklin, G. Novel p38 inhibitors with potent oral efficacy in several models of rheumatoid arthritis. Bioorg. Med. Chem. Lett., 2004, 14, 3595-3599.
32. Alfonso de Dios, Chuan Shih, Beatriz Lopez de Uralde, Concepcion Sanchez, Miriam del Prado, Luisa M. Marti{dotless}n Cabrejas, Sehila Pleite, Jaime Blanco-Urgoiti, Mari{dotless}a Jose Lorite, C. Richard Nevill Jr., Rosanne Bonjouklian, Jeremy York, Michal Vieth, Yong Wang, Nicholas Magnus, Robert M. Campbell, Bryan D. Anderson, Denis J. McCann, Deborah D. Giera, Paul A. Lee, Richard M. Schultz, Li C. Li, Lea M. Johnson and Jeffrey A. Wolos. Design of potent and selective 2-aminobenzimidazole-based p38 MAP Kinase inhibitors with excellent in vivo efficacy. J. Med. Chem., 2005, 48, 2270-2273.
33. Hammach, A.; Barbosa, A.; Gaenzler, F. C.; Fadra, T.; Goldberg, D.; Ming-Hong Hao, Kroe, R. R.; Liu, P.; Qian, K. C.; Ralph, M.; Sarko, C.; Soleymanzadeh, F.; Moss, N. Discovery and design of benzimidazolone based inhibitors of p38 MAP kinase. Bioorg. Med. Chem. Lett., 2006, 16, 6316-6320.
34. Pierre, K.; Christiane, B.; Hartmut, J.; Stefan, L. Targeting the Ribose and Phosphate Binding Site of p38 Mitogen-Activated Protein (MAP) Kinase: Synthesis and biological testing of 2-alkylsulfanyl-, 4(5)-aryl-, 5(4)-heteroaryl-substituted imidazoles. J. Med. Chem., 2008, 51, 5630-5640.
35. Renata B. L.; Cleverton K. F. de Lima; Leandro L. da Silva; Nelilma C. Romeiro; Ana Luisa P. Miranda; Eliezer J. Barreiro; Carlos A. M. Fraga. Discovery of novel analgesic and anti-inflammatory 3-arylamine-imidazo[1, 2-a]pyridine symbiotic prototypes. Bioorg. Med. Chem., 2009, 17, 74-84.
36. Li, J.; Kaoud, T. S.; Laroche, C.; Dalby, K. N.; Kerwin, S. M. Synthesis and biological evaluation of p38a kinase-targeting dialkynylimidazoles. Bioorg. Med. Chem. Lett., 2009, 19, 6293-6297.
37. Regan, J.; Breitfelder, S.; Cirillo, P.; Gilmore, T.; Graham, A. G.; Hickey, E.; Klaus, B.; Madwed, J.; Moriak, M.; Moss, N.; Pargellis, C.; Pav, S.; Proto, A.; Swinamer, A.; Tong, L.; Torcellini, C. Pyrazole urea-based inhibitors of p38 MAP Kinase: From lead compound to clinical candidate. J. Med. Chem., 2002, 45, 2994-3008.
38. Dumas, J.; Sibley, R.; Riedl, B.; Monahan, M. K.; Lee, W.; Lowinger, T. B.; Redman, A. M.; Johnson, J. S.; Kingery-Wood, J.; Scott, W. J.; Smith, R. A.; Bobko, M.; Schoenleber, R.; Ranges, G. E.; Housley, T. J.; Bhargava, A.; Wilhelm, S. M.; Shrikhande, A. Discovery of a new class of p38 Kinase inhibitors. Bioorg. Med. Chem. Lett., 2000, 10, 2047-2050.
39. Dumas, J.; Hatoum-Mokdad, H.; Sibley, R.; Riedl, B.; Scott, W. J.; Monahan, M. K.; Lowinger, T. B.; Brennan, C.; Natero, R.; Turner, T.; Johnson, J. S.; Schoenleber, R.; Bhargava, A.; Wilhelm, S. M.; Housley, T. J.; Ranges, G. E.; Shrikhande, A. 1-Phenyl-5-pyrazolyl ureas: potent and selective p38 Kinase inhibitors. Bioorg. Med. Chem. Lett., 2000, 10, 2051-2054.
40. Dumas, J.; Hatoum-Mokdad, H.; Sibley, R. N.; Smith, R. A.; Scott, W. J.; Khire, U.; Lee, W.; Wood, J.; Wolanin, D.; Cooley, J.; Bankston, D.; Redman, A. M.; Schoenleber, R.; Caringal, Y.; Gunn, D.; Romero, R.; Osterhout, M.; Paulsen, H.; Housley, T. J.; Wilhelm, S. M.; Pirro, J.; Du-Shieng Chien,.; Ranges, G. E.; Shrikhande, A.; Muzsi, A.; Bortolon, E.; Wakefield, J.; Ostravage, C. G.; Bhargava, A.; Chaub, T. Synthesis and pharmacological characterization of a potent, orally active p38 Kinase inhibitor. Bioorg. Med. Chem. Lett., 2002, 12, 1559-1562.
41. Redman, A. M.; Johnson, J. S.; Dally, R.; Swartz, S.; Wild, H.; Paulsen, H.; Caringal, Y.; Gunn, D.; Renick, J.; Osterhout, M.; Kingery-Wood, J.; Smith, R. A.; Lee, W.; Dumas, J.; Wilhelm, S. M.; Housley, T. J.; Bhargava, A.; Ranges, G. E.; Shrikhande, A.; Young, D.; Bombara, M.; Scott, W. J. p38 Kinase inhibitors for the treatment of arthritis and osteoporosis: Thienyl, Furyl, and Pyrrolyl Ureas. Bioorg. Med. Chem. Lett., 2001, 11, 9-12.
42. Regan, J.; Capolino, A.; Cirillo, P. F.; Gilmore, T.; Graham, A. G.; Hickey, E.; Kroe, R. R.; Madwed, J.; Moriak, M.; Nelson, R.; Pargellis, C. A.; Swinamer, A.; Torcellini, C.; Tsang, M.; Moss, N. Structure-Activity Relationships of the p38 MAP Kinase Inhibitor 1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-ylethoxy) naphthalen-1-yl]urea (BIRB 796). J. Med. Chem., 2003, 46, 4676-4686.
43. Wan, Z.; Boehm, J. C.; Bower, M. J.; Kassis, S.; Lee, J. C.; Zhao, Adams, J. L. N-Phenyl-N-purin-6-yl ureas: The design and synthesis of P38 MAP Kinase inhibitors. Bioorg. Med. Chem. Lett., 2003, 13, 1191-1194.
44. Moss, N.; Breitfelder, S.; Betageri, R.; Cirillo, P. F.; Fadra, T.; Hickey, E. R.; Kirrane, T.; Kroe, R. R.; Madwed, J.; Nelson, R. M.; Pargellis, C. A.; Qian, K. C.; Regan, J.; Swinamer, A.; Torcellini, C. New modifications to the area of pyrazole-naphthyl urea based p38 MAP kinase inhibitors that bind to the adenine/ATP site. Bioorg. Med. Chem. Lett., 2007, 17, 4242-4247.
45. Cirillo, P. F.; Hickey, E. R.; Moss, N.; Breitfelder, S.; Betageri, R.; Fadra, T.; Gaenzler, F.; Gilmore, T.; Goldberg, D. R.; Kamhi, V.; Kirrane, T.; Kroe, R. R.; Madwed, J.; Moriak, M.; Netherton, M.; Pargellis, C. A.; Patel, U. R.; Qian, K. C.; Sharma, R.; Sun, S.; Swinamer, A.; Torcellini, C.; Takahashi, H.; Tsang, M.; Xiong, Z. Discovery and characterization of the N-phenyl-N'-naphthylurea class of p38 kinase inhibitors. Bioorg. Med. Chem. Lett., 2009, 19, 2386-2391.
46. Liu, H.; Kuhn, C.; Feru, F.; Jacques, S. L.; Deshmukh, G. D.; Ye, P.; Rennie, G. R.; Johnson, T.; Kazmirski, S.; Low, S.; Coli, R.; Yuan-hua Ding.; Cheng, A. C.; Tecle, H.; English, J. M.; Stanton, R.; Wub, J. C. Enhanced selectivity profile of pyrazole-urea based DFG-out p38 inhibitors. Bioorg. Med. Chem. Lett., 2010, 20, 4885-4891.
47. Getlik, M, Grütter. C, Simard. J. R, Nguyen. H. D, Robubi. A,; Aust. B, van Otterlo. W. A. L.; Rauh. D. Structure-based design, synthesis and biological evaluation of N-pyrazole, N'-thiazole urea inhibitors of MAP kinase p38. Eur. J. Med. Chem., 2012, 48, 1-15.
48. R. de O. Lopes; Romeiro. N. C.; de Lima, C. K. F.; da Silva, L. L.; de Miranda, A. L. P.; Nascimento, P. Gustavo B. D.; Cunha, F. Q.; Barreiro, E. J.; Lima, L. M. Docking, synthesis and pharmacological activity of novel urea-derivatives designed as p38 MAPK inhibitors. Eur. J. Med. Chem., 2012, 54, 264-271.
49. Goldstein, D. M.; Alfredson, T.; Bertrand, J.; Browner, M. F.; Clifford, K.; Dalrymple, S. A.; Dunn, J.; Freire-Moar, J.; Harris, S.; Labadie, S. S.; Fargue, J. L.; Lapierre, J. M.; Larrabee, S.; Li, F.; Papp, E.; McWeeney, D.; Ramesha, C.; Roberts, R.; Rotstein, D.; Pablo, B. S.; Sjogren, E. B.; On-Yee So, Talamas, F. X.; Tao, W.; Trejo, A.; Villasenor, A.; Welch, M.; Welch, T.; Weller, P.; Whiteley, E.; Young, K.; Zipfel, S. Discovery of S-[5-Amino-1-(4-fluorophenyl)-1H-pyrazol-4-yl]-[3-(2, 3-dihydroxypropoxy) phenyl]-methanone (RO3201195), an orally bioavailable and highly selective inhibitor of p38 MAP Kinase. J. Med. Chem., 2006, 49, 1562-1575.
50. Barnes, M. J.; Conroy, R.; Miller, D. J.; Mills, J. S.; Montana, J. G.; Pooni, P. K.; Showell, G. A.; Walsh, L. M.; Warneck, J. B. H. Trimethylsilylpyrazoles as novel inhibitors of p38 MAP kinase: A new use of silicon bioisosteres in medicinal chemistry. Bioorg. Med. Chem. Lett., 2007, 17, 354-357.
51. Graneto, M. J.; Kurumbail, R. G.; Vazquez, M. L.; Shieh, H. S.; Pawlitz, J. L.; Williams, J. M.; Stallings, W. C.; Geng, L.; Naraian, A. S.; Koszyk, F. J.; Stealey, M. A.; Xu, X. D.; Weier, R. M.; Hanson, G. J.; Mourey, R. J.; Compton, R. P.; Mnich, S. J.; Anderson, G. D.; Monahan, J. B.; Devraj, R. Synthesis, crystal structure, and activity of pyrazole-based inhibitors of p38 Kinase. J. Med. Chem., 2007, 50, 5712-5719.
52. Walker, J. K.; Selness S. R.; Devraj, R. V.; Hepperle, M. E.; Naing, W.; Shieh, H.; Kurambail, R.; Yang, S.; Flynn, D. L.; Benson, A. G.; Messing, D. M.; Dice, T.; Kim, T.; Lindmark, R. J.; Monahan, J. B.; Portanova, J. Identification of SD-0006, a potent diaryl pyrazole inhibitor of p38 MAP kinase. Bioorg. Med. Chem. Lett., 2010, 20, 2634-2638.
53. Das, J.; Moquin, R. V.; Dyckman, A. J.; Li, T.; Pitt, S.; Zhang, R.; Shen, D. R.; McIntyre, K. W.; Gillooly, K.; Doweyko, A. M.; Newitt, J. A.; Sack, J. S.; Zhang, H.; Kiefer, S. E.; Kish, K.; McKinnon, M.; Barrish, J. C.; Dodd, J. H.; Schieven, G. L.; Leftheris, K. 5-Aminopyrazoles as potent and selective p38 inhibitors. Bioorg. Med. Chem. Lett., 2010, 20, 6886-6889.
54. Revesz, L.; Blum, E.; Di Padova, F. E.; Buhl, T.; Feifel, R.; Gram, H.; Hiestand, P.; Manning, U.; Neumann, U.; Rucklin, G. Pyrazoloheteroaryls: Novel p38 MAP kinase inhibiting scaffolds with oral activity. Bioorg. Med. Chem. Lett., 2006, 16, 262-266.
55. Das, J.; Moquin, R. V.; Pitt, S.; Zhang, R.; Shen, D. R.; McIntyre, K. W.; Gillooly, K.; Doweyko, A. M.; Sack, J. S.; Zhang, H.; Kiefer, S. E.; Kish, K.; McKinnon, M.; Barrish, J. C.; Dodd, J. H.; Schieven, G. L.; Leftheris, K. Pyrazolo-pyrimidines: A novel heterocyclic scaffold for potent and selective p38 inhibitors. Bioorg. Med. Chem. Lett., 2008, 18, 2652-2657.
56. Cheung, M.; Harris, P. A.; Badiang, J. G.; Peckham, G. E.; Chamberlain, S. D.; Alberti, M. J.; Jung, D. K.; Harris, S. S.; Bramson, N. H.; Epperly, A. H.; Stimpson, S. A.; Peel, M. R. The identification of pyrazolo[1, 5-a]pyridines as potent p38 kinase inhibitors. Bioorg. Med. Chem. Lett., 2008, 18, 5428-5430.
57. Wurz, R. P.; Pettus, L. H.; Xu, S.; Henkle, B.; Sherman, L.; Plant, M.; Miner, K.; McBride, H.; Wong, L. M.; Saris, C. J. M.; Lee, M. R.; Chmait, S.; Mohr, C.; Hsieh, F.; Tasker, A. S. Part 1: Structure-activity relationship (SAR) investigations of fused pyrazoles as potent, selective and orally available inhibitors of p38 mitogen-activated protein kinase. Bioorg. Med. Chem. Lett., 2009, 19, 4724-4728.
58. Wurz, R. P.; Pettus, L. H.; Henkle, B.; Sherman, L.; Plant, M. Miner, K.; McBride, H. J.; Wong, L. M.; Saris, C. J. M.; Lee, M. R.; Chmait, S.; Mohr, C.; Hsieh, F.; Tasker, A. S. Part 2: Structure-activity relationship (SAR) investigations of fused pyrazoles as potent, selective and orally available inhibitors of p38 mitogen-activated protein kinase. Bioorg. Med. Chem. Lett., 2010, 20, 1680-1684.
59. Pettus, L. H.; Wurz, R. P.; Xu, S.; Herberich, B.; Henkle, B.; Liu, Q.; McBride, H. J.; Mu, S.; Plant, M. H.; Saris, C. J. M.; Sherman, L.; Wong, L. M.; Chmait, S.; Lee, M. R.; Mohr, C.; Hsieh, F.; Tasker, A. S. Discovery and evaluation of 7-alkyl-1, 5-bis-aryl-pyrazolopyridinones as highly potent, selective, and orally efficacious inhibitors of p38 Mitogen-Activated Protein Kinase. J. Med. Chem., 2010, 53, 2973-2985.
60. Soth, M.; Abbot, S.; Abubakari, A.; Arora, N.; Arzeno, H.; Billedeau, R.; Dewdney, N.; Durkin, K.; Frauchiger, S.; Ghate, M.; Goldstein, D. M.; Hill, R. J.; Kuglstatter, A.; Li. F.; Loe. B.; McCaleb, K.; McIntosh, J.; Papp, E.; Park, J.; Stahl, M.; Man-Ling, S.; Suttman, R.; David, C.; Swinney, W. P.; Wong, B.; Zeci, H.; Gabriel, T. 3-Aminopyrazolo[3, 4-d]pyrimidines as p38 kinase inhibitors: Design and development to a highly selective lead. Bioorg. Med. Chem. Lett., 2011, 21, 3452-3456.
61. Tamayo, N.; Liao, L.; Goldberg, M.; Powers, D.; Tudor, Y. Y.; Yu, V.; Wong, L. M.; Henkle, B.; Middleton, S.; Syed, R.; Harvey, T.; Jang, G.; Hungate, R.; Dominguez, C. Design and synthesis of potent pyridazine inhibitors of p38 MAP kinase. Bioorg. Med. Chem. Lett., 2005, 15, 2409-2413.
62. Natarajan, S. R.; Heller, S. T.; Nam, K.; Singh, S. B.; Scapin, G.; Patel, S.; Thompson, J. E.; Fitzgerald, C. E.; O'Keefe, S. J. p38 MAP kinase inhibitors. Part 6: 2-Arylpyridazin-3-ones as templates for inhibitor design. Bioorg. Med. Chem. Lett., 2006, 16, 5809-5813.
63. Jerome, K. D.; Hepperle, M. E.; Walker, J. K.; Xing, L.; Devraj, R. V.; Benson, A. G.; Baldus, J. E.; Selness, S. R. Discovery of 5-substituted-N-arylpyridazinones as inhibitors of p38 MAP kinase. Bioorg. Med. Chem. Lett., 2010, 20, 3146-3149.
64. Murali Dhar, T. G.; Wrobleski, S. T.; Lin, S.; Furch, J. A.; Nirschl, D. S.; Fan, Y.; Todderud, G.; Pitt, S.; Doweyko, A. M.; Sack, J. S.; Mathur, A.; McKinnon, M.; Barrish, J. C.; Dodd, H.; Schieven, G. L.; Leftheris, K. Synthesis and SAR of p38 MAP kinase inhibitors based on heterobicyclic scaffolds. Bioorg. Med. Chem. Lett., 2007, 17, 5019-5024.
65. Tan, X.; Tester, R. W.; Luedtke, G. R.; Chakravarty, S.; Mavunkel, B. J.; Perumattam, J. J.; Lu, Q.; Nashashibi, I.; Jung, J.; Hu, J.; Liclican, A.; Almirez, R.; Tabora, J.; Tran, V.; Laney, M.; Levy, D. E.; Dugar, S. Design and synthesis of piperazine-indole p38 MAP kinase inhibitors with improved pharmacokinetic profiles. Bioorg. Med. Chem. Lett., 2010, 20, 828-831.
66. Mavunkel, B. J.; Perumattam, J. J.; Tan, X.; Luedtke, G. R.; Lu, Q.; Lim, D.; Kizer, D.; Dugar, S.; Chakravarty, S.; Yong-jin Xu, Jung, J.; Liclican, A.; Levy, D. E.; Tabora, J. Piperidine-based heterocyclic oxalyl amides as potent p38 MAP kinase inhibitors. Bioorg. Med. Chem. Lett., 2010, 20, 1059-1062.
67. Montalban, A. G.; Boman, E.; Chang, C. D.; Ceide, S. C.; Dahl, R.; Dalesandro, D.; Delaet, N. G. J.; Erb, E.; Gibbs, A.; Kahl, J.; Kessler, L.; Lundström, J.; Miller, S.; Nakanishi, H.; Roberts, E.; Saiah, E.; Sullivan, R.; Wang, Z.; Larson, C. J. 'Reverse' ketoamide-based p38 MAP kinase inhibitors Bioorg. Med. Chem. Lett., 2008, 18, 5456-5459.
68. Montalban, A. G.; Boman, E.; Chang, C. D.; Ceide, S. C.; Dahl, R.; Dalesandro, D.; Delaet, N. G. J.; Erb, E.; Ernst, J. T.; Gibbs, A.; Kahl, J.; Kessler, L.; Kucharski, J.; Lum, C.; Lundström, J.; Miller, S.; Nakanishi, H.; Roberts, E.; Saiah, E.; Sullivan, R.; Urban, J.; Wang, Z.; Larson, C. J. Optimization of ketoamide based p38 inhibitors through modifications to the region that binds to the allosteric site. Bioorg. Med. Chem. Lett., 2010, 20, 4819-4824.
69. Cogan, D. A.; Aungst, R.; Breinlinger, E. C.; Fadra, T.; Goldberg, D. R.; Hao, M. H.; Kroe, R.; Moss, N.; Pargellis, C.; Qiana, K. C.; Swinamer, A. D. Structure-based design and subsequent optimization of 2-tolyl-(1, 2, 3-triazol-1-yl-4-carboxamide) inhibitors of p38 MAP kinase. Bioorg. Med. Chem. Lett., 2008, 18, 3251-3255.
70. Angell, R. M.; Bamborough, P.; Cleasby, A.; Cockerill, S. G.; Jones, K. L.; Mooney, C. J.; Somers, D. O.; Walker, A. L. Biphenyl amide p38 kinase inhibitors 1: Discovery and binding mode. Bioorg. Med. Chem. Lett., 2008, 18, 318-323.
71. Aston, N. M.; Bamborough, P.; Buckton, J. B.; Edwards, C. D.; Holmes, D. S.; Jones, K. L.; Patel, V. K.; Smee, P. A.; Somers, D. O.; Vitulli, G.; Walker, A. L. p38 Mitogen-Activated Protein Kinase inhibitors: Optimization of a series of biphenylamides to give a molecule suitable for clinical progression. J. Med. Chem., 2009, 52, 6257-6269.
72. Luedtke, G. R.; Schinzel, K.; Tan, X.; Tester, R. W.; Nashashibi, I.; Xu, Y. j.; Dugar, S.; Levy, D. E.; Jung, J. Amide-based inhibitors of p38 MAP kinase. Part 1: Discovery of novel N-pyridyl amide lead molecules. Bioorg. Med. Chem. Lett., 2010, 20, 2556-2559.
73. Tester, R.; Tan, X.; Luedtke, G. R.; Nashashibi, I.; Schinzel, K.; Liang, W.; Jung, J.; Dugar, S.; Liclican, A.; Tabora, J.; Levy, D. E.; Do, S. Amide-based inhibitors of p38 MAP kinase. Part 2: Design, synthesis and SAR of potent N-pyrimidyl amides. Bioorg. Med. Chem. Lett., 2010, 20, 2560-2563.
74. Revesz, L.; Di Padova, F. E.; Buhl, T.; Feifel, R.; Gram, H.; Hiestand, P.; Manning, U.; Zimmerlin, A. G. SAR of 4-hydroxypiperidine and hydroxyalkyl substituted heterocycles as novel p38 MAP Kinase inhibitors. Bioorg. Med. Chem. Lett., 2000, 10, 1261-1264.
75. Revesz, L.; Blum, E.; Di Padova, F. E.; Buhl, T.; Feifel, R.; Gram, H.; Hiestand, P.; Manning, U.; Rucklin, G. SAR of benzoylpyridines and benzophenones as p38 MAP kinase inhibitors with oral activity. Bioorg. Med. Chem. Lett., 2004, 14, 3601-3605.
76. Bullington, J.; Argentieri, D.; Averill, K.; Carter, D.; Cavender, D.; Fahmy, B.; Fan, X.; Hall, D.; Heintzelman, G.; Jackson, P.; Leung, W. P.; Li, X.; Ling, P.; Olini, G.; Razler, T.; Reuman, M.; Rupert, K.; Russell, R.; Siekierka, J.; Wadsworth, S.; Wolff, R.; Xiang, B.; Zhanga, Y. M. Inhibitors of unactivated p38 MAP kinase. Bioorg. Med. Chem. Lett., 2006, 16, 6102-6106.
77. McClure, K. F.; Letavic, M. A.; Kalgutkar, A. S.; Gabel, C. A.; Audoly, L.; Barberia, J. T.; Braganza, J. F.; Carter, D.; Carty, T. J.; Cortina, S. R.; Dombroski, M. A.; Donahue, K. M.; Elliott, N. C.; Gibbons, C. P.; Jordan, C. K.; Kuperman, A. V.; Labasi, J. M.; LaLiberte, R. E.; McCoy, J. M.; Naiman, B. M.; Nelson, K. L.; Nguyen, H. T.; Peese, K. M.; Sweeney, F. J.; Taylor, T. J.; Trebino, C. E.; Abramov, Y. A.; Laird, E. R.; Volberg, W. A.; Zhou, J.; Bach, J.; Lombardo, F. Structure-activity relationships of triazolopyridine oxazole p38 inhibitors: Identification of candidates for clinical development. Bioorg. Med. Chem. Lett., 2006, 16, 4339-4344.
78. Jerome, K. D.; Rucker, P. V.; Xing, L.; Shieh, H. S.; Baldus, J. E.; Selness, S. R.; Letavic, M. A.; Braganza, J. F.; McClure, K. F. Continued exploration of the triazolopyridine scaffold as a platform for p38 MAP kinase inhibition. Bioorg. Med. Chem. Lett., 2010, 20, 469-473.